Strepelle has been brought to market by Luas Diagnostics to provide an easy to use and accessible home-to-laboratory test for Group B Strep to safeguard babies and their families. 

Many advanced countries routinely test for Group B Strep, but the UK does not. A Group B Strep trial is underway in the UK and the results will be used to inform the future of pregnancy care across the United Kingdom but until testing is offered universally the risks of this damaging infection remain and it is the task of private providers such as Strepelle to supply the highest quality testing and support services to pregnant mothers.

We are on a mission to increase the knowledge and reduce the impact of Group B Strep. Testing significantly reduces the risk of Group B Strep infection becoming a life-threatening condition; once discovered, treatment is highly effective. Most early onset Group B Strep infections are preventable.